UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 306

Sortiert nach

Impact of Primary Elvitegravir Resistance-Associated Mutations in HIV-1 Integrase on Drug Susceptibility and Viral Replication Fitness

Antimicrobial Agents and Chemotherapy, 2013-06, Vol.57 (6), p.2654-2663

2013

Link zum Volltext

Verfügbarkeit prüfen

Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome

PloS one, 2017-02, Vol.12 (2), p.e0172206-e0172206

2017

Link zum Volltext

Verfügbarkeit prüfen

Phenotypic Susceptibility to Bevirimat in Isolates from HIV-1-Infected Patients without Prior Exposure to Bevirimat

Antimicrobial Agents and Chemotherapy, 2010-06, Vol.54 (6), p.2345-2353

2010

Link zum Volltext

Verfügbarkeit prüfen

Resistance Analyses in Highly Treatment-Experienced People With Human Immunodeficiency Virus (HIV) Treated With the Novel Capsid HIV Inhibitor Lenacapavir

The Journal of infectious diseases, 2022-11, Vol.226 (11), p.1985-1991

2022

Link zum Volltext

Verfügbarkeit prüfen

Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection

The New England journal of medicine, 2022-05, Vol.386 (19), p.1793-1803

2022

Link zum Volltext

Verfügbarkeit prüfen

Molecular Mechanisms of Resistance to Human Immunodeficiency Virus Type 1 with Reverse Transcriptase Mutations K65R and K65R+M184V and Their Effects on Enzyme Function and Viral Replication Capacity

Antimicrobial Agents and Chemotherapy, 2002-11, Vol.46 (11), p.3437-3446

2002

Link zum Volltext

Verfügbarkeit prüfen

Characterization of HIV-1 Resistance to Tenofovir Alafenamide In Vitro

Antimicrobial agents and chemotherapy, 2015-10, Vol.59 (10), p.5917-5924

2015

Link zum Volltext

Verfügbarkeit prüfen

Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment–Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide

The Journal of infectious diseases, 2017-03, Vol.215 (6), p.920-927

2017

Link zum Volltext

Verfügbarkeit prüfen

High resistance barrier to tenofovir alafenamide is driven by higher loading of tenofovir diphosphate into target cells compared to tenofovir disoproxil fumarate

Antiviral research, 2016-08, Vol.132, p.50-58

2016

Link zum Volltext

Verfügbarkeit prüfen

Antiviral activity of HIV‐1 integrase strand‐transfer inhibitors against mutants with integrase resistance‐associated mutations and their frequency in treatment‐naïve individuals

Journal of medical virology, 2019-12, Vol.91 (12), p.2188-2194

2019

Link zum Volltext

Verfügbarkeit prüfen

A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RT

AIDS (London), 2005-11, Vol.19 (16), p.1751-1760

2005

Link zum Volltext

Verfügbarkeit prüfen

ATP-Dependent Removal of Nucleoside Reverse Transcriptase Inhibitors by Human Immunodeficiency Virus Type 1 Reverse Transcriptase

Antimicrobial Agents and Chemotherapy, 2002-07, Vol.46 (7), p.2179-2184

2002

Link zum Volltext

Verfügbarkeit prüfen

Effects of the Translocation Status of Human Immunodeficiency Virus Type 1 Reverse Transcriptase on the Efficiency of Excision of Tenofovir

Antimicrobial Agents and Chemotherapy, 2007-08, Vol.51 (8), p.2911-2919

2007

Link zum Volltext

Verfügbarkeit prüfen

Molecular Mechanisms of Tenofovir Resistance Conferred by Human Immunodeficiency Virus Type 1 Reverse Transcriptase Containing a Diserine Insertion after Residue 69 and Multiple Thymidine Analog-Associated Mutations

Antimicrobial Agents and Chemotherapy, 2004-03, Vol.48 (3), p.992-1003

2004

Link zum Volltext

Verfügbarkeit prüfen

The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations

Antiviral therapy, 2006-01, Vol.11 (2), p.155-163

2006

Link zum Volltext

Verfügbarkeit prüfen

Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy

AIDS (London), 2011-01, Vol.25 (3), p.325-333

2011

Link zum Volltext

Verfügbarkeit prüfen

In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4

Antiviral research, 2012-02, Vol.93 (2), p.288-296

2012

Link zum Volltext

Verfügbarkeit prüfen

Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934

Journal of acquired immune deficiency syndromes (1999), 2009-10, Vol.52 (2), p.209

2009

Link zum Volltext

Verfügbarkeit prüfen

The Balance between NRTI Discrimination and Excision Drives the Susceptibility of HIV-1 RT Mutants K65R, M184V and K65R+M184V

Antiviral chemistry & chemotherapy, 2007-12, Vol.18 (6), p.307-316

2007

Link zum Volltext

Verfügbarkeit prüfen

Nucleoside Reverse Transcriptase Inhibitor Resistance Mutations Associated with First-Line Stavudine-Containing Antiretroviral Therapy: Programmatic Implications for Countries Phasing Out Stavudine

The Internet journal of infectious diseases, 2013-06, Vol.207 (suppl_2), p.S70-S77

2013

Link zum Volltext

Verfügbarkeit prüfen

Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF

AIDS (London), 2002-06, Vol.16 (9), p.1227-1235

2002

Link zum Volltext

Verfügbarkeit prüfen

Virologic and Enzymatic Studies Revealing the Mechanism of K65R- and Q151M-Associated HIV-1 Drug Resistance Towards Emtricitabine and Lamivudine

Nucleosides, nucleotides & nucleic acids, 2006-01, Vol.25 (1), p.89-107

2006

Link zum Volltext

Verfügbarkeit prüfen

The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation

Journal of acquired immune deficiency syndromes (1999), 2008-08, Vol.48 (4), p.428

2008

Link zum Volltext

Verfügbarkeit prüfen

Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine

Journal of acquired immune deficiency syndromes (1999), 2007-10, Vol.46 (2), p.174

2007

Link zum Volltext

Verfügbarkeit prüfen

Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses

Journal of acquired immune deficiency syndromes (1999), 2003-05, Vol.33 (1), p.15

2003

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 306

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(283)
Mit Volltextzugriff
(281)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Impact of Primary Elvitegravir Resistance-Associated Mutations in HIV-1 Integrase on Drug Susceptibility and Viral Replication Fitness

Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome

Phenotypic Susceptibility to Bevirimat in Isolates from HIV-1-Infected Patients without Prior Exposure to Bevirimat

Resistance Analyses in Highly Treatment-Experienced People With Human Immunodeficiency Virus (HIV) Treated With the Novel Capsid HIV Inhibitor Lenacapavir

Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection

Molecular Mechanisms of Resistance to Human Immunodeficiency Virus Type 1 with Reverse Transcriptase Mutations K65R and K65R+M184V and Their Effects on Enzyme Function and Viral Replication Capacity

Characterization of HIV-1 Resistance to Tenofovir Alafenamide In Vitro

Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment–Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide

High resistance barrier to tenofovir alafenamide is driven by higher loading of tenofovir diphosphate into target cells compared to tenofovir disoproxil fumarate

Antiviral activity of HIV‐1 integrase strand‐transfer inhibitors against mutants with integrase resistance‐associated mutations and their frequency in treatment‐naïve individuals

A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RT

ATP-Dependent Removal of Nucleoside Reverse Transcriptase Inhibitors by Human Immunodeficiency Virus Type 1 Reverse Transcriptase

Effects of the Translocation Status of Human Immunodeficiency Virus Type 1 Reverse Transcriptase on the Efficiency of Excision of Tenofovir

Molecular Mechanisms of Tenofovir Resistance Conferred by Human Immunodeficiency Virus Type 1 Reverse Transcriptase Containing a Diserine Insertion after Residue 69 and Multiple Thymidine Analog-Associated Mutations

The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations

Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy

In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4

Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934

The Balance between NRTI Discrimination and Excision Drives the Susceptibility of HIV-1 RT Mutants K65R, M184V and K65R+M184V

Nucleoside Reverse Transcriptase Inhibitor Resistance Mutations Associated with First-Line Stavudine-Containing Antiretroviral Therapy: Programmatic Implications for Countries Phasing Out Stavudine

Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF

Virologic and Enzymatic Studies Revealing the Mechanism of K65R- and Q151M-Associated HIV-1 Drug Resistance Towards Emtricitabine and Lamivudine

The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation

Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine

Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses

Suchergebnisse filtern